Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Net Cash Flow (2016 - 2025)

Voyager Therapeutics' Net Cash Flow history spans 11 years, with the latest figure at $17.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 142.03% year-over-year to $17.3 million; the TTM value through Dec 2025 reached -$6.2 million, down 261.34%, while the annual FY2025 figure was -$6.2 million, 261.34% down from the prior year.
  • Net Cash Flow for Q4 2025 was $17.3 million at Voyager Therapeutics, up from $3.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $169.4 million in Q1 2023 and bottomed at -$179.0 million in Q3 2023.
  • The 5-year median for Net Cash Flow is $3.5 million (2023), against an average of -$1.9 million.
  • The largest annual shift saw Net Cash Flow tumbled 119673.33% in 2022 before it soared 1072.87% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $6.0 million in 2021, then tumbled by 64.77% to $2.1 million in 2022, then skyrocketed by 68.32% to $3.5 million in 2023, then plummeted by 1264.96% to -$41.2 million in 2024, then skyrocketed by 142.03% to $17.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Net Cash Flow are $17.3 million (Q4 2025), $3.9 million (Q3 2025), and -$30.8 million (Q2 2025).